Support

Quick links
Frequently asked questions - categories
Ask a question
Contact Us
+1

MHC-II Monoclonal Mouse Antibody (IPO-10)

MAb IPO-10 defines the antigen that appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym.

Product Attributes

Antibody number

1090

Reactivity (target)

MHC-II

Antibody type

Primary

Host species

Mouse

Clonality

Monoclonal

Clone

IPO-10

Isotype

IgG3, kappa

Molecular weight

36 kDa

Human gene symbol

HLA-DRA

Entrez gene ID

3122

SwissProt

P01903

Unigene

520048

Immunogen

Spleen cells of a patient with hairy cell leukemia (Daudi cells)

Cellular localization

Membrane/cell surface

Species reactivity

Monkey, Human

Applications

Immunofluorescence, Flow cytometry

Application notes

Immunofluorescence 0.5-1 ug/mL, Flow Cytometry 0.5-1 ug/million cells/0.1 mL, Optimal dilution for a specific application should be determined by user

Positive control

Ramos, Daudi or HuT78 cells. Tonsil or lymph node

Shipping condition

Room temperature

Storage Conditions

Store at 2 to 8 °C, Protect fluorescent conjugates from light, Note: store BSA-free antibodies at -10 to -35 °C

Shelf life

Guaranteed for at least 24 months from date of receipt when stored as recommended

Regulatory status

For research use only (RUO)

Research areas

Immunology, MHC antigens

Conjugation
Size
Catalog #
price
Qty
50 uL
100 uL
250 uL
500 uL
Clear selection
Add to wishlist
ADD TO CART
(Please select quantity above )

Wishlist updated! View wishlist

Shipping, Handling & Tax (CA only) not included in price. Learn more

Tax is assessed in the state of California. All fees will be calculated during checkout based on your shipping information and are subject to change.

SPECIAL - Order 5 or more and receive 10% off.

Request a Bulk Quote

Product Description

MAb IPO-10 defines the antigen that appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin’s disease cases a significant percentage of affected lymph node cells were detected.

Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. See the CF® Dye Brochure for more information. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Stock status: Because Biotium offers a large number of antibody and conjugation options, primary antibody conjugates may be made to order. Typical lead times are up to one week for CF® dye and biotin conjugates, and up to 2-3 weeks for fluorescent protein and enzyme conjugates. Please email order@biotium.com to inquire about stock status and lead times before placing your order.

 Catalog number key for antibody number 1090, Anti-MHC-II (IPO-10) The prefix indicates conjugation, followed by the antibody number and size suffix.

Antibody # prefixConjugationEx/EmConcentrationStorage Buffer
BNC04CF®405S404/431 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC05CF®405M408/452 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC88CF®488A490/515 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC43CF®543541/560 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC55CF®555555/565 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC68CF®568562/583 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC94CF®594593/614 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC40CF®640R642/662 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC47CF®647650/665 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC61CF®660R663/682 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC80CF®680681/698 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC81CF®680R680/701 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNC70CF®770770/797 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCRR-PE (PE)496, 546, 565/578 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCAAPC650/660 nnm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCPPerCP482/677 nm0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCBBiotinN/A0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCAPAlkaline PhosphataseN/A0.1 mg/mL PBS, 0.1% BSA, 0.05% azide
BNCHHorseradish PeroxidaseN/A0.1 mg/mL PBS, 0.05% BSA, no azide
BNUBPurified, with BSA N/A0.2 mg/mL PBS, 0.05% BSA, 0.05% azide
BNUMPurified, BSA-freeN/A1 mg/mL PBS, no BSA, no azide

References

Pinchouk V.G. et al., Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. Anticancer Research 8, 1377-1380, 1988. | Gluzman D.F. et al., Monoclonal antibodies IPO-3, IPO-4 and IPO-10 against lymphocyte differentiation antigens. Tissue Antigens 33, 151, 1989. | Sidorenko S.P. et al., Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping. Neoplasma 39, 3-9, 1992

 

You may also like…